Elicio ELI-002 7P Shows Complete Responses in mKRAS PDAC
Elicio Therapeutics hosted a key opinion leader event to highlight the path forward for its drug candidate, ELI-002 7P, in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma (mKRAS PDAC). The event showcased promising preliminary clinical data, including 100% confirmed complete radiographic and metabolic responses in three patients who received ELI-002 7P followed by nivolumab-based therapy. These rare and durable responses in a difficult-to-treat patient population support the company's plan to initiate a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition in first-line mPDAC.
Key Highlights
- Three patients achieved 100% confirmed complete radiographic and metabolic responses after ELI-002 7P and subsequent nivolumab-based therapy.
- Complete responses were observed in MSS/MMR-proficient metastatic PDAC, a population rarely responsive to checkpoint inhibition.
- Two of the three complete responses were maintained for at least 9 months, including one ongoing response.
- Elicio Therapeutics plans a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition in first-line mPDAC.
- The planned Phase 1 study aims to verify the clinical signal and inform future development plans.
- Key opinion leaders Zev Wainberg, M.D., and Peter Hosein, M.D., presented at the event.
Price Impact
More from ELTX
Elicio Therapeutics Reports Multiple Complete Responses in Pancreatic Cancer
Elicio Reports 3 Complete Responses in Pancreatic Cancer; Plans Phase 1 Study
Elicio Therapeutics Refines Phase 3 Strategy After Pancreatic Cancer Study Results